Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by StockingUp21on Jul 21, 2021 1:04pm
110 Views
Post# 33581825

RE:RE:RE:What's that smell?

RE:RE:RE:What's that smell?

gamepump, until another deal nuance can be questionable. For only 20 million they could have doubled money shorting all this way. Show me credible pharma who cares Remember you say they contact hundreds of companies for deals? No chance of any progress here. Because of inside sales. 


GameChangerBet wrote: Forest, your opinion about Antibe is shared by Nuance who backed up their opinion with a  $100usd contract.
123ABC has his opinion backed up by yukonjeza.

I wouldn't be too worried...



 

Forestview wrote: For someone that can't wait for the price to go up so that he can break even and sell, you sure love to focus on the down days and continue to drive the fear and uncertainty messaging.  Great plan.  Keep planting doubt here for retail investors to read, you'll breakeven in no time.  

123ABC wrote: Oh, ATE is red again.

 




<< Previous
Bullboard Posts
Next >>